Genmab (GMAB) said Tuesday that the global net trade sales of Darzalez (daratumumab), as reported by Johnson & Johnson (JNJ), were $3.24 billion in the first quarter.
Genmab receives royalties on the worldwide net sales of Darzalex under the exclusive worldwide license to Johnson & Johnson to develop, manufacture and commercialize daratumumab, the biotechnology company said.
Darzalex net sales also included sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename Darzalex Faspro in the US, the company said.
Of the total, net trade sales were $1.83 billion in the US and $1.41 billion in the rest of the world, the company said.
Price: 19.44, Change: +0.12, Percent Change: +0.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。